Jorge Kizer, M.D.
Dr. Jorge Kizer's research focuses on advancing understanding of biochemical and imaging determinants of cardiovascular disease and stroke, with the goal of improving diagnosis and treatment of these disorders. His key areas of interest are obesity and the aging process, and how bioactive factors secreted by adipocytes, skeletal myocytes, and cardiomyocytes, among other cell types, lead to dysregulation of homeostatic mechanisms and promote the development of metabolic and cardiovascular diseases.
After receiving a medical degree from the University of Pennsylvania, Dr. Kizer completed his residency in internal medicine at Brigham and Women’s Hospital. He subsequently earned a master of science in epidemiology from the Harvard School of Public Health, and went on to complete a cardiovascular fellowship at the University of Pennsylvania Medical Center. He came to Einstein-Montefiore from Weill Cornell Medical College, where he was Associate Professor of Medicine and Public Health.
Dr. Kizer has been an investigator in several NIH-funded population based studies, principally the Strong Heart Study and the Cardiovascular Health Study, and his work has been funded by research awards from the National Heart, Lung, and Blood Institute and the American Heart Association. He serves as Editor of the Clinical Trials and their Interpretation section for Current Atherosclerosis Reports.
- Kizer JR, Arnold AM, Benkeser D, Ix JH, Djousse L, Zieman SJ, Barzilay JI, Tracy RP, Mantzoros CS, Siscovick DS, Mukamal KJ. Total and High-Molecular-Weight Adiponectin and Risk of Incident Diabetes in Older People. Diabetes Care 2012;35:415-423.
- Karas MG, Devereux RB, Wiebers DO, Whisnant JP, Best LG, Lee ET, Howard BV, Roman MJ, Umans JG, Kizer JR. Incremental Value of Biochemical and Echocardiographic Measures in Prediction of Ischemic Stroke: The Strong Heart Study. Stroke 2012;43:720-726.
- Kizer JR, Umans JG, Zhu J, Devereux RB, Wolfert RL, Lee ET, Howard BV. Lipoprotein-Associated Phospholipase A2 Mass and Activity and Risk of Cardiovascular Disease in a Population with High Prevalences of Obesity and Diabetes: The Strong Heart Study. Diabetes Care 2012;35:840-847.
Kizer JR, Benkeser D, Arnold AM, Mukamal KJ, Ix JH, Zieman SJ, Siscovick DS, Tracy RP, Mantzoros CS, deFilippi CR, Newman AB, Djousse L. Associations of Total and High-Molecular-Weight Adiponectin with All-cause and Cardiovascular Mortality in Older Persons: The Cardiovascular Health Study. Circulation 2012;126:2951-2961.
- Kizer JR, Benkeser D, Arnold AM, Djousse L, Zieman, SJ, Mukamal KJ, Tracy RP, Mantzoros CS, Siscovick DS, Gottdiener JS, Ix JH. Total and High-Molecular-Weight Adiponectin and Risk of Coronary Heart Disease and Ischemic Stroke in Older Adults. J Clin Endocrinol Metab 2013;98:255-263.
- Kizer JR. A Tangled Threesome: Adiponectin, Insulin Sensitivity and Adiposity. Can Mendelian Randomization Sort Out Causality? Diabetes 2013;62:1007-1009.
- Kizer JR. Enhancing Detection of Subclinical End-Organ Damage: Echocardiographic Left Ventricular Strain Holds Up a Mirror to the Brain. Circulation 2013;128:1045-1047.
- Karas MG, Benkeser D, Arnold AM, Bartz TM, Djousse L, Mukamal KJ, Ix JH, Zieman SJ, Siscovick DS, Tracy RP, Mantzoros CS, Gottdiener JS, deFilippi C, Kizer JR. Relations of Total and High-Molecular-Weight Adiponectin to New-Onset Heart Failure in Adults >=65 Years of Age (From the Cardiovascular Health Study). Am J Cardiol 2014;113:328-334.
Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.